Navigation Links
Protein handlers should be effective treatment target for cancer and Alzheimer's
Date:8/6/2009

AUGUSTA, Ga. Cancer and Alzheimer's have excess protein in common and scientists say learning more about how proteins are made and eliminated will lead to better treatment for both.

Medical College of Georgia researchers Drs. Nahid F. Mivechi and Dimitrios Moskofidis have received two National Cancer Institute grants totaling nearly $3 million and a $982,800, four-year grant from the U.S. Department of Veterans Affairs in the last 12 months to support studies of proteins and the molecular chaperones that manage them from cradle to grave.

Understanding the exact role molecular chaperones play in cancer and Alzheimer's should lead to better ways to intervene in both, says Dr. Mivechi, director of the MCG Center for Molecular Chaperone Biology/Radiobiology and Cancer Virology.

Everyone needs molecular chaperones which prompt genes to make proteins, move proteins around the body, fold them up into the proper shape to function properly and even haul them off when they no longer work. Cancer needs them even more for the endless cell replication required for tumor growth, Dr. Mivechi says. Essentially the opposite happens in Alzheimer's in which excess protein is a major component of the destructive brain plaque that is the disease's hallmark. Dr. Mivechi believes molecular chaperones, which typically slow in activity with age, are failing at their job so that proteins aggregate in the brain, contributing to Alzheimer's and other neurodegenerative diseases in which brain cell communication is interrupted.

The MCG center has evidence that disabling molecular chaperones or the heat shock factors that control some of them, disables tumor formation in the liver and probably the breast. Researchers are also now examining brain tumors as well as pancreatic and prostate cancer.

They also want to know whether ramping up the activity of molecular chaperone can essentially make them act young again and halt development of Alzheimer's, Parkinson's and other neurodegenerative diseases.

"We have to find the balance," Dr. Mivechi says of the center's concurrent work to find drugs that adjust the activity of molecular chaperones and heat shock factors. She theorizes these drugs would be used for limited periods to avoid trading cancer for an increased risk of neurodegenerative disease or vice versa.

"A lot of drugs, such as chemotherapeutic agents, can kill cancer but they also kill normal tissue. That is a limiting factor. We are looking for better drugs," she says.

The MCG center is among the first to study molecular chaperones and heat shock factors in animals to better understand their role in these diseases. Drs. Mivechi and Moskofidis, a viral immunologist, have developed 20 mouse models missing different molecular chaperones or heat shock factors in the last decade to help explore the large family of molecular chaperones. For contrast, they also have a mouse that over expresses heat shock factor 1, or Hsf1, a major activator of molecular chaperones.

They are now focusing on developing mice that lack molecular chaperones or heat shock factors in targeted areas, such as liver or breast tissue, as well as mice in which these can be removed during cancer to determine what impact their loss has on active disease. They also are cross breeding the mice, to create one, for example, that also over expresses the molecule, Her2/Neu, which is over active in some of the most aggressive breast cancers. By comparing the resulting mouse to one that just over expresses Her2/Neu, they can examine the impact of Hsf1, Dr. Mivechi says.

"That is how these findings will translate to patients," Dr. Mivechi says. "We need to know, not only how deleting or augmenting molecular chaperones and heat shock factors affects disease development, but also how it impacts disease progression."

Their studies also will help researchers pinpoint which molecular chaperones and/or heat shock factors are associated with a specific type of cancer or neurodegenerative disease which will help in the design of targeted therapies.

With the VA-funded study, for example, when they remove a specific molecular chaperone they find Alzheimer's-like disease accelerates dramatically in their animal model. They want to expand these studies to look at traumatic brain injury as well as other neurodegenerative diseases.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related biology news :

1. Pitt researchers find promising candidate protein for cancer prevention vaccines
2. Structure of protective protein in the eye lens revealed
3. Little-known protein found to be key player
4. New computer simulation helps explain folding in important cellular protein
5. Protein that promotes cancer cell growth identified
6. Sticky protein helps reinforce fragile muscle membranes
7. Plant protein doorkeepers block invading microbes, study finds
8. Protein can help cells or cause cancer, Purdue researcher finds
9. Plant protein doorkeepers block invading microbes, study finds
10. Structural biology scores with protein snapshot
11. Proteins in gel
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Protein handlers should be effective treatment target for cancer and Alzheimer's
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not many ... of the most crucial aspects of recovery so we need to do it well. ... risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... and find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... , December 8, 2016 The report "Acrylic Processing Aid Market by ... Packaging, Automotive, Consumer Goods) - Global Forecast to 2026", published by MarketsandMarkets, the ... reach USD 1,173.6 Million by 2026, registering an of CAGR of 6.2% between ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, ... developing breakthrough immune modulatory medicines, announced today the initiation ... lead therapeutic candidate, LYC-30937- E nteric C oated, ... skin disease that is estimated to affect as many ... , with approximately 1.5 - 3 million cases ...
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO USA is ... cart. The new website has been designed to provide the best user-friendly experience ... to access detailed product information, read educational industry content as well as share ...
(Date:12/6/2016)... Dec. 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... the fourth quarter and fiscal year ended September 30, 2016. ... , , ... life sciences and diagnostics company that develops and commercializes proprietary technologies ... Achieved revenues of $1.4 million more than tripling ...
Breaking Biology Technology: